# Remedy Robotics

> Developer of the investigational N1 robot for image-guided, remotely operable endovascular procedures.

## Why it is interesting

Its November 16, 2026 $62M Series B, led by DCVC, is intended to fund a pivotal trial and FDA review rather than scale sales of an approved product. Remote neurovascular procedures have been reported in small first-in-human studies, but no approved commercial device or validated economic outcome has been established.

## Profile

- **Latest funding:** Series B — $62M (November 16, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $62M
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-16
- **Latest funding investors:** DCVC, UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, KdT Ventures

## Key facts

- $62M Series B announced Nov 16, 2026, led by DCVC; legal settlement date and valuation undisclosed.
- New investors UC Investments, Skip Capital and Hostplus; returning Build Collective, Blackbird, Divergent Capital and KdT Ventures.
- Company reports relationships with over 100 hospitals, NOT 100 commercial deployments or proven outcomes.
- N1 remains an investigational device; FDA clearance or approval has not been established.

## Funding history

- Series B · $62M · November 16, 2026
  Source: https://www.prnewswire.com/news-releases/remedy-robotics-raises-62-million-series-b-to-bring-life-saving-cardiovascular-intervention-to-patients-everywhere-302939871.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/remedy-robotics
